Newsletter · · Ashutosh Agarwal

Novo Stumbles and Lilly's Pipeline Shines Into Wednesday Earnings - Week of August 3, 2026

A synthesis of what investor, clinical and industry podcasts said about the weight-loss drug complex for the week ending August 3, 2026, ahead of Novo Nordisk and Eli Lilly reporting on the same Wednesday, including a failed heart-outcomes trial, a courtroom fight over whether retatrutide counts as a biologic, and Medicare's first weight-loss coverage.

Novo Nordisk & Eli Lilly

Week of August 3, 2026: Novo Stumbles and Lilly's Pipeline Shines Into Wednesday Earnings

The two giants of the weight-loss world both report earnings this Wednesday, and they walk in with very different body language. Novo Nordisk just watched a big trial go the wrong way and shed billions in a day. Eli Lilly walks in as the biggest profit story on Wall Street outside of artificial intelligence, with a pipeline investors have fallen in love with. Underneath the earnings drama, three quieter stories moved this week: an obscure court case that could reshape who gets to make these drugs, a wave of new Medicare coverage, and the slow realization that the pill era is here but messier than the hype suggested.

TL;DR

  • Novo Nordisk sank on a failed heart-outcomes trial (roughly $15 billion of market value gone), while its Wegovy pill is being called one of the best drug launches ever. Both Novo and Lilly report Q2 on Wednesday, August 5.
  • Lilly's story has shifted from today's products to tomorrow's pipeline, its triple-hormone drug retatrutide (up to 29% weight loss) and a separate court fight over whether it counts as a "biologic," which would hand Lilly 12 years of protection and lock out cheaper copycats.
  • The money math is changing fast: drug prices are down 60-70%, volumes are exploding, Medicare now covers weight-loss drugs for the first time at a $50 copay, and the ripples are reaching everything from CPAP machines to potato chips.

What's new

Novo's trial miss versus one of the best launches in history. On CNBC's "Fast Money" (July 31), Mizuho healthcare analyst Jared Holtz walked through Novo Nordisk sinking after a cardiovascular outcomes trial failed, a study meant to prove the drug prevents heart attacks and strokes, not just weight. The panel pegged the damage at "a 15 billion dollar reduction in market cap" on what was "potentially a multi-billion dollar sales opportunity." Holtz wouldn't bury the drug entirely ("these studies are very tricky... the odds are obviously very low"), but the read-through matters: Novo needs its pipeline to show investors there's life beyond obesity. The strange part is the contrast. As trader Tim Seymour put it, Novo "gets no credit whatsoever for one of the most successful drug launches in history," the Wegovy pill, which Holtz called "a monster launch, one of the best we've ever seen." CNBC's "Fast Money"

Lilly is now valued for its pipeline, not its shelf. On Barron's Streetwise (July 31), host Jack Howe and Morgan Stanley's head of US pharma and biotech, Terrence Flynn, laid out the scale. Lilly is expected to earn $31 billion in 2026, up 36%, and "by 2030, that figure could double," putting it near JPMorgan in raw profit power, the only non-AI company in that league. Morgan Stanley just raised its 2035 forecast for the whole GLP-1 market from $150 billion to $190 billion, which assumes about 30% of obese Americans are on these drugs by then, up from just 6% last year. On the same show, analyst Jared Holtz flagged the twist: investors have "gravitated away from Fandeo" (Lilly's new pill) "and towards retitrutide," Lilly's next-generation injection. In plain terms, the market has stopped caring about what Lilly sells today and started paying for what it might sell in two years. Barron's Streetwise · CNBC's "Fast Money"

A courtroom fight almost nobody is watching could reshape the whole industry. This was the most underappreciated development of the week, and it came from a patient-focused show. On On The Pen GLP-1 News (July 28), host Dave Knapp explained that Lilly told investors last week, for the first time openly, that it intends to file retatrutide as a "biologic." (A biologic is a drug made from living systems; legally it earns 12 years of protection from competition instead of the usual five, and copies can only be rough "biosimilars," not cheap generics.) The catch: the FDA says a protein needs more than 40 amino-acid building blocks to qualify, and retatrutide has exactly 40. A judge sided with the FDA on the technicality but called part of the agency's reasoning "arbitrary and capricious" and sent it back for a do-over. Oral arguments are set for September 24, 2026, in Chicago. Why a weight-loss newsletter cares: as Knapp warned, a new definition wouldn't stop at one drug, it could sweep in the entire next generation of appetite drugs and, more importantly, decide whether cheaper compounded versions survive at all. And Lilly's willingness to announce the filing "signals that they have a fairly high degree of confidence." On The Pen GLP-1 News

Medicare opened the door, with a trapdoor. Multiple shows flagged the same July 1 change: for the first time, Medicare will pay for these drugs purely for weight loss. On Medicine: The Truth (July 29), former Kaiser Permanente CEO Dr. Robert Pearl explained the details. The copay is $50 a month, "about 80% less than the price" cash payers face. But it's a temporary 18-month pilot (the "BRIDGE program"), built as a workaround because Congress still bans weight-loss-only coverage. The government pays roughly $245 a month per prescription, and of Medicare's ~70 million members, about 30 million would qualify, though 16 million already get the drugs through existing diabetes or sleep-apnea coverage. Pearl's honest caveat is the one investors should underline: "most patients regain the weight they lost if they stop taking the GLP-1 medications," so if the pilot lapses in 18 months, the benefit could vanish with it. Medicine: The Truth with Dr. Robert Pearl and Jeremy Corr

Price is falling faster than volume can catch up, for now. On PwC's Next in Health (July 30), the firm's Phil Sclafati gave the cleanest summary of the payer's dilemma: GLP-1 "prices have come down upwards of 60, 70 percent," but "volume has skyrocketed and could further 2x, 3x and 4x from there. There simply isn't enough price left to offset." Employers are paying "30, 40, 50 dollars per member per month" just for these drugs, and 2027 will be "topsy-turvy," some employers adding coverage, "a pretty good amount" dropping or restricting weight-loss coverage while keeping it for diabetes. His hopeful analogy: statins were once seen as not worth paying for, and now they're routine; GLP-1s "may get there... but it's going to take time to develop the evidence base." PwC's Next in Health

The debate

The bull case (well-voiced this week). Terrence Flynn of Morgan Stanley made the strongest version on Barron's Streetwise: these drugs increasingly look like an "everything pill." Beyond weight, they're being studied in heart disease, kidney disease, sleep apnea, addiction, and even Alzheimer's, because they appear to calm the chronic inflammation that sits underneath many diseases. Flynn's key point for numbers people: "If these drugs are successful at showing benefits in brain diseases, mental health conditions, or inflammatory conditions, that could open additional adjacent markets... not fully reflected in our numbers or consensus numbers." That's the upside nobody has fully modeled yet. Barron's Streetwise

The bear case (also voiced, from two directions). First, on efficacy: on Weight and Healthcare (August 1), Ragen Chastain dug into the actual Phase 3 results for Lilly's new pill, orforglipron (brand name Foundayo/Foundeo). Average weight loss was modest, 7.5%, 8.4%, and 11.2% across the three doses, and even at the top dose, "28.2% failed to lose even 5%" and 45.4% failed to lose 10%. She also stressed the study was designed and run by Lilly with Lilly-funded authors. In other words, the pill that was supposed to bring these drugs to the masses is real, but it is not the miracle the injections are. That squares with the market reaction Jared Holtz described, the pill "has been relatively disappointing." Second, on the newest injection: Holtz openly questioned whether the world needs retatrutide's extra firepower. Near-30% weight loss sounds huge, but "you can get there with the higher doses that the existing drugs give or take," so it's "very incremental" and risks simply cannibalizing today's sales rather than expanding the market. Weight and Healthcare · CNBC's "Fast Money"

The names in play

  • Novo Nordisk (NVO): the loser of the week on the failed heart-outcomes trial, but the Wegovy pill is "one of the best" launches ever and the stock is "de-risked" per the Fast Money traders. Reports Wednesday. CNBC's "Fast Money"
  • Eli Lilly (LLY): the market's darling, now priced on the pipeline (retatrutide, plus an early amylin drug "Alluralintide" that preserves muscle) more than on today's Zepbound or the underwhelming Foundeo pill. Reports Wednesday; the September 24 biologic hearing is a real catalyst. Barron's Streetwise · On The Pen GLP-1 News

Read-throughs

Sleep apnea and CPAP (ResMed, Inspire): less of a threat than the fear trade assumes. On JAMA Clinical Reviews (July 29), sleep researcher Dr. Atul Malhotra, an investigator on the trial that got tirzepatide approved for sleep apnea in 2024, noted the drug delivers "18 to 20% weight loss with concomitant improvements in sleep apnea severity." But he pushed back on the idea that pills kill CPAP machines: there are "about a billion people worldwide with obstructive sleep apnea," a number "increasing, not decreasing over time, even with GLP-1 receptor agonists," and "Nasal CPAP... is still first-line treatment," with the drugs "adjunctive." The read-through: GLP-1s expand the diagnosed-and-treated pool as much as they shrink it. JAMA Clinical Reviews

Heart failure: a genuine clinical tailwind. On Cardionerds (July 29), Dr. John Ostrominski described the STEP-HFpEF trial, where a GLP-1 improved patients' quality-of-life score by about 8 points, "nearly identical" to what a targeted, disease-specific heart drug achieves. His line: "If that doesn't emphasize the importance of intervening on obesity... I'm really not sure what will." Cardiologists are being told to prescribe these drugs themselves, which widens the funnel well beyond obesity clinics. Cardionerds: A Cardiology Podcast

Glucose monitors (Dexcom, Abbott): a companion, not a casualty. On Hormones & Hope (July 30), endocrinologist Dr. Chhaya recommended pairing a continuous glucose monitor with GLP-1 treatment for diabetics and for weight patients with metabolic issues, a reminder that the two technologies sell together rather than compete. Hormones & Hope with Dr. Chhaya

Packaged food (PepsiCo, General Mills): reformulate or lose volume. On Taste Radio (July 31), the hosts unpacked a Wall Street Journal interview with PepsiCo CEO Ramon Laguarta on navigating GLP-1s and inflation. PepsiCo cut prices on Doritos and Lay's, "choosing volume over margins," and General Mills did the same, both getting about 1% growth for it. Meanwhile they're chasing the appetite-suppressed shopper with functionality: protein added to Honey Nut Cheerios, fiber to Annie's fruit snacks. Taste Radio

The snack that wins: protein. On the Closing Market Report (July 30), CoBank livestock economist Abby Groves said GLP-1 users have become a real demand driver for single-serve, high-protein meat snacks, people "snacking more... because their appetite has been reduced" and reaching for a low-calorie, high-protein stick instead of a meal. Roughly $8 billion has gone into animal-protein processing over five to six years, about $1 billion of it specifically for meat snacks. Closing Market Report

One thing worth flagging on access

On What's Health Got to Do with It? (August 1), the hosts reminded listeners how much GLP-1 use still runs through compounding pharmacies and "research" versions sold by telehealth clinics and med spas, with roughly 34 states allowing the light-touch licensing that makes it possible. This is the exact market the retatrutide biologic fight could shut down. Keep the two stories connected: the courtroom in Chicago and the med-spa down the street are part of the same question about who gets to make these drugs and at what price. What's Health Got to Do with It?